Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has reported Non-Current Deffered Revenue for 5 consecutive years, with $253.4 million the latest figure, recorded in Q1 2025.

• Quarterly Non-Current Deffered Revenue rose 10.92% year-over-year to $253.4 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $253.4 million (up 10.92% YoY) and the FY2024 annual result came in at $244.6 million, up 43.13% from the prior year.
• Non-Current Deffered Revenue improved to $253.4 million in Q1 2025 per AUTL's latest filing, from $244.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for AUTL reached as high as $253.4 million in Q1 2025 and fell as low as $47.0 million in Q4 2021.
• A 5-year average of $151.2 million and a median of $138.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 168.44% — and 2025, when it increased 10.92%.
• Year by year, Non-Current Deffered Revenue stood at $47.0 million in 2021, then surged by 167.78% to $125.9 million in 2022, then soared by 35.74% to $170.9 million in 2023, then surged by 43.13% to $244.6 million in 2024, then grew by 3.61% to $253.4 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $253.4 million, $244.6 million, and $248.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.